萨雷普塔治疗公司每股亏损3.58美元, 收入下降32.7%, 但ELEVIDYS获得FDA批准, 公司在2026年保持现金流正值. Sarepta Therapeutics lost $3.58 per share, revenue dropped 32.7%, but ELEVIDYS got FDA approval and the company stays cash flow positive in 2026.

Sarepta治疗机构报告,每股季度损失3.58美元,缺少估计数,因为全年收入下降32.7%,同时病人和医生仍然犹豫不决,并有很长的注入时间。 Sarepta Therapeutics reported a quarterly loss of $3.58 per share, missing estimates, as revenue fell 32.7% year-over-year amid ongoing patient and physician hesitancy and long infusion timelines. PMO特许经营权产生了2.59亿美元的收入,达90%以上合规率,该公司预计2026年将保持现金顺流,同时推进五个临床阶段的SIRNA方案,预计到季度末将有早期数据。 The PMO franchise generated $259 million in revenue with over 90% compliance, and the company expects to remain cash flow positive in 2026 while advancing five clinical-stage siRNA programs, with early data expected by quarter-end. 根据长期安全数据,ELEVIDYS获得了FDA对外诊患者的传统批准,并计划在第一季度末召开FDA会议. ELEVIDYS received traditional FDA approval for ambulatory patients, supported by long-term safety data, and a late-first-quarter FDA meeting is planned. 首席执行官Doug Ingram将在2026年晚些时候退休,引入执行风险。 CEO Doug Ingram will retire by late 2026, introducing execution risk. 股价上0.13美元至18.97美元, 交易量高于平均水平, 分析师维持"持有"评级. The stock rose $0.13 to $18.97 on higher-than-average volume, with analysts maintaining a mixed "Hold" rating.